文献类型：期刊文献

中文题名：PARP1及PARP抑制剂在肝细胞癌中的临床作用研究进展

英文题名：Research progress on the clinical role of PARP1 and PARP inhibitors in hepatocellular carcinoma

作者：朱玲玲[1,2,3];张亚妮[1,3];伍杨[1,3];史婷婷[1,3];何昱静[3];张久聪[3]

第一作者：朱玲玲

机构：[1]甘肃中医药大学第一临床医学院,甘肃兰州730000;[2]庆阳市人民医院感染科;[3]中国人民解放军联勤保障部队第九四〇医院消化内科

第一机构：甘肃中医药大学临床医学院

年份：2026

卷号：35

期号：3

起止页码：464

中文期刊名：胃肠病学和肝病学杂志

外文期刊名：Chinese Journal of Gastroenterology and Hepatology

基金：中央高校优秀青年团队培育项目(31920220065);甘肃省卫生健康行业科研计划项目(GSWSKY2023-34;GSWSKY2022)。

语种：中文

中文关键词：PARP1;PARP抑制剂;肝细胞癌

外文关键词：Poly(ADP-ribose)polymerases 1;Poly(ADP-ribose)polymerases inhibitors;Hepatocellular carcinoma

摘要：肝细胞癌(hepatocellular carcinoma,HCC)发病率在全球范围内不断增长,超过50%的HCC患者在诊断时已是疾病晚期。聚(ADP-核糖)聚合酶1[poly(ADP-ribose)polymerases 1,PARP1]是一种普遍存在的核酶,参与多种细胞过程,包括DNA修复、凋亡、基因组稳定性和细胞分裂等。PARP1在DNA断裂修复中起重要作用,已被证明在HCC中高表达并调控HCC进展。作为HCC候选治疗靶点,PARP抑制剂(PARP inhibitors,PARPi)可与多种化疗药物协同抗HCC。本文就PARP1如何调控HCC进展及对HCC放化疗的影响进行探讨,并总结PARPi对HCC作用的分子机制,以期为HCC提供新的治疗方向。
The incidence of hepatocellular carcinoma(HCC)is increasing worldwide,and more than 50%of HCC patients have advanced disease at the time of diagnosis.Poly(ADP-ribose)polymerases 1(PARP1)is a ubiquitous ribozyme involved in a variety of cellular processes,including DNA repair,apoptosis,genome stability and cell division.PARP1,which plays an important role in DNA break repair,has been shown to be highly expressed in HCC and regulate HCC progression.As a candidate therapeutic target for HCC,PARP inhibitors(PARPi)can synergise with a variety of chemotherapy drugs against HCC.In this review,we discussed how PARP1 regulates the progression of HCC and its effect on radiotherapy and chemotherapy,and summarized the molecular mechanism of PARPi on HCC,in order to provide a new direction for the treatment of HCC.